Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down - What's Next?

Key Points

• Chugai Pharmaceutical's shares opened at $22.54 after previously closing at $23.55, highlighting a significant gap down prior to trading on Thursday.
• The company reported earnings of $0.20 per share for the last quarter, with a net margin of 33.08% and projected an EPS of 0.74 for the current fiscal year.
• Chugai Pharmaceutical has a market cap of $77.16 billion and operates in the research and development of pharmaceuticals in Japan and internationally.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) shares gapped down prior to trading on Thursday . The stock had previously closed at $23.55, but opened at $22.54. Chugai Pharmaceutical shares last traded at $23.53, with a volume of 22,719 shares changing hands.

Chugai Pharmaceutical Price Performance

The stock's fifty day moving average is $22.70 and its 200-day moving average is $24.45. The stock has a market cap of $77.16 billion, a PE ratio of 29.68 and a beta of 0.64.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The company reported $0.20 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 33.08% and a return on equity of 20.80%. The firm had revenue of $2.01 billion during the quarter. On average, sell-side analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.